Biocon Prepares For Life After Pfizer
This article was originally published in PharmAsia News
Following the dissolution of its global biosimilars deal with Pfizer, Biocon Chairman Kiran Mazumdar-Shaw speaks with PharmAsia News about the path ahead.
You may also be interested in...
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.